Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older

With the emergence of the severe acute respiratory syndrome 2 (SARS-CoV-2) B.1.1.529/BA.1 (Omicron) variant in early 2022, Israel began vaccinating individuals 6o years of age or older with a fourth BNT162b2 vaccine. While the decision was based on little experimental data, longer follow-up showed c...

Descripción completa

Detalles Bibliográficos
Autores principales: Saiag, Esther, Alcalay, Yifat, Marudi, Or, Orr-Urtreger, Avi, Hagin, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767892/
https://www.ncbi.nlm.nih.gov/pubmed/36572602
http://dx.doi.org/10.1016/j.vaccine.2022.12.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767892/
https://www.ncbi.nlm.nih.gov/pubmed/36572602
http://dx.doi.org/10.1016/j.vaccine.2022.12.035

Ejemplares similares